What are the options for Tuberculosis (TB) testing?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 4, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

The most appropriate option for TB testing is the Interferon-Gamma Release Assay (IGRA), which is preferred over the tuberculin skin test (TST) for individuals who have received the BCG vaccine or are unlikely to return for TST reading, as recommended by the American Thoracic Society, Centers for Disease Control and Prevention, and Infectious Diseases Society of America 1.

Options for TB Testing

There are several options for tuberculosis (TB) testing, with the two main categories being skin tests and blood tests. The tuberculin skin test (TST), also known as the Mantoux test, involves injecting a small amount of purified protein derivative (PPD) under the skin of the forearm and checking for a reaction 48-72 hours later. A positive reaction, indicated by induration (hardened area) of 5-15mm depending on risk factors, suggests TB infection.

Blood Tests

Blood tests, known as Interferon-Gamma Release Assays (IGRAs), include QuantiFERON-TB Gold Plus and T-SPOT.TB, which measure the immune response to TB proteins in a blood sample. IGRAs are generally preferred for people who have received the BCG vaccine since they don't cross-react with the vaccine like the skin test can.

Factors Influencing Test Choice

The choice between tests depends on factors like:

  • Previous BCG vaccination
  • Age
  • Immune status
  • Local availability Testing is particularly important for high-risk groups including:
  • Close contacts of TB patients
  • Immunocompromised individuals
  • Healthcare workers
  • Those from countries with high TB prevalence

Additional Tests for Active TB

For active TB disease diagnosis, additional tests include:

  • Chest X-rays
  • Sputum microscopy
  • Culture tests
  • Molecular tests like GeneXpert MTB/RIF, which can detect TB bacteria and rifampin resistance within hours As noted in the 2019 study, guidelines by WHO, USPSTF, ATS, CDC, and IDSA support testing with IGRA over TST for diagnosis of LTBI in individuals with low-to-intermediate risk of progression to active disease, and either IGRA or TST or dual testing (if first one is negative) at highest risk of developing active MTB 1.

From the Research

Options for TB Testing

There are several options available for TB testing, including:

  • Tuberculin skin test (TST)
  • Interferon-gamma release assays (IGRAs) such as T-SPOT.TB and QuantiFERON-TB Gold In-Tube (QFT-GIT) 2, 3, 4
  • C-Tb skin test, a novel specific skin test based on ESAT-6 and CFP10 antigens 5

Characteristics of TB Tests

The characteristics of these tests are:

  • TST: less sensitive and specific than IGRAs, especially in BCG-vaccinated populations 2, 3
  • IGRAs: more sensitive and specific than TST, especially in BCG-vaccinated populations 2, 3, 4, 6
  • C-Tb skin test: delivers IGRA-like results in a field-friendly format, unaffected by BCG vaccination status 5

Predictive Value of TB Tests

The predictive value of these tests for the progression of latent infection to active tuberculosis disease is:

  • IGRAs: better predictive ability than TST, with a pooled risk ratio of 9.35 (95% CI 6.48-13.49) compared to 4.24 (3.30-5.46) for TST 4
  • TST: lower predictive ability, with a pooled positive predictive value of 2.3% (1.5-3.1) compared to 4.5% (3.3-5.8) for IGRAs 4

Recommendations for TB Testing

Based on the available evidence, the following recommendations can be made:

  • IGRAs are preferred for BCG-vaccinated populations and for individuals with high risk of progression to active TB 2, 3, 4, 6
  • C-Tb skin test may be a useful alternative to IGRAs in certain settings 5
  • Dual testing with IGRAs and TST may improve detection, but further confirmation is needed 4

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.